Retrotope

7 articles with Retrotope

• US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

  2/18/2020

  Retrotope announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug for the treatment of Progressive SupraNuclear Palsy.

• Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)Three clinical trials centers now open for enrollment; two additional ones initiating

  1/9/2020

  Retrotope announced that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias.

• Parkinson’s Institute and Clinical Center and Retrotope Announce Collaboration on New Drug Treatment Therapies for Parkinson’s Disease Patients

  10/4/2018

  Parkinson’s Institute and Clinical Center and Retrotope announced today a collaboration on a new drug therapy to treat patients with Progressive SupraNuclear Palsy.

• 

  FDA Grants Orphan Drug Designation for Retrotope's RT001 in the Treatment of Phospholipase 2G6 (P...

  11/2/2017

  Physicians collaborating with Retrotope previously received approval from the FDA to test RT001 in Expanded Access trials of two patients having Infantile Neuroaxonal Dystrophy.

• Retrotope To Present First Human Data On Safety And Early Efficacy Of RT001 With Neurodegeneration At American Academy of Neurology Meeting

  4/25/2017

• Retrotope And Collaborators To Present Poster At American Academy of Neurology On Stabilized PUFA Drug Efficacy In Multiple Alzheimer’s Models

  4/25/2017

• Retrotope Announces Phase I/II Clinical Trial Results Of RT001 In Treatment Of Friedreich’s Ataxia

  9/16/2016